Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
about
Bortezomib for the treatment of multiple myelomaMultiple myeloma in the very elderly patient: challenges and solutionsEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisEuropean perspective on multiple myeloma treatment strategies in 2014New criteria for response assessment: role of minimal residual disease in multiple myelomaThe role of maintenance therapy in multiple myelomaOptimal maintenance and consolidation therapy for multiple myeloma in actual clinical practiceClinical use of proteasome inhibitors in the treatment of multiple myelomaAre maintenance and continuous therapies indicated for every patient with multiple myeloma?Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapiesCuring myeloma at last: defining criteria and providing the evidence.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomaPhase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaThalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up.Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.ESRD due to Multiple Myeloma in the United States, 2001-2010.Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.Comparing efficacy and survivals of initial treatments for elderly patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials.New approaches to management of multiple myeloma.Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Carfilzomib in multiple myeloma.Therapeutic advancements in multiple myeloma.Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group.The role of pre-transplant induction regimens and autologous stem cell transplantation in the era of novel targeted agents.Current therapeutic strategies for multiple myeloma.Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma.An update in treatment options for multiple myeloma in nontransplant eligible patients.Managing multiple myeloma in elderly patients.Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.Oral ixazomib maintenance therapy in multiple myeloma.New pharmacotherapy options for multiple myeloma.Nuances in the Management of Older People With Multiple Myeloma.
P2860
Q24185881-1E0D0D4E-6458-49DC-90F2-FB9FC5A92345Q26752991-082F1570-94A2-4CCD-B204-4B0A2A5E83C0Q26767418-3C322EEE-94EC-411F-82FB-4247107BB8A6Q27005966-59FAEDCB-D39E-43BF-85CA-C429BA136599Q27027512-14389C03-288B-45A9-A6F9-92110FFE1284Q28071644-F4560E76-4946-4F90-81A7-DA5B04B3B6F6Q28077567-7738F0EC-B9E2-4319-B3FF-189DB3C16159Q28080999-DBF70B2E-5F04-4ED7-9D75-85A7C0A5FE13Q30249790-0DB59F8B-AEF0-4E4D-B747-81C2AE094197Q31136560-0577FD35-ACEA-4BC8-89FE-5D91D8E9EDCDQ33431175-83DE4A11-5ADA-4BBD-A635-C3DFC3B8F420Q33443411-9BB63A0D-080D-492E-8547-7D67B8BE8E86Q34272540-9766A265-638E-4890-824C-96E184F5B3A2Q34508313-431BB3B3-61AB-44E8-82D3-3EBE66B1F053Q35789280-DE28E1A4-FD1E-493C-80FF-614E64731BC4Q35907767-C60B4211-1B85-4DDD-871E-965A8CEA84E4Q35932505-03D9A66B-3D68-4234-9137-E02F453FECABQ36051084-685DB111-4F7E-48AE-963B-F32F145825D8Q36115680-FC7E099E-8F49-4B44-9308-EF259A77F593Q36592788-995FEE66-46B1-496A-B04C-5FDA62BB7530Q36839385-03E0F64C-6171-4045-B024-77BA756F1C7CQ36849170-E392F814-CE4B-4864-B89A-689291908A5BQ37216380-4779C798-1177-4F30-89A6-A92F050B864EQ37414394-497C6C27-6117-4633-A505-55F457329E63Q37536148-A328D0C4-9FDD-41CB-814A-F0454BF3CC81Q38191867-88B19821-BC28-4788-9ECB-44ACAF526420Q38218209-1129A3A7-2BA7-4BEB-A584-5F2DEAA50FDBQ38232055-59D0A5F9-F514-44A8-904E-01104F8773F2Q38244558-0861EC2D-E238-411C-AAF1-5BC434884E4DQ38252583-AD051C15-7AD8-4EC9-8277-4C8173C5E235Q38367249-CDCA3072-00F3-475B-82A1-06142A350079Q38375463-C62FF057-7202-4447-AF36-3021CE9CC518Q38412189-0CF1AAB8-17E8-4FBB-9316-F7E15A697AD2Q38555091-BA5C73D4-9DD6-4291-AAD0-3370BAB1F613Q38561373-0B5938C9-7875-42E9-969C-8768CBBF73ABQ38605484-140F13DD-503B-480A-AD9E-D02A2524E5FEQ38637962-6D0CF510-B958-4A58-8443-659DDA5409FCQ38640514-64ABFFAE-D8FE-46CF-84A0-2311E000CAFAQ38673764-B259DAE3-1110-42F1-9E82-A958EE4792EFQ38796491-CAA059F5-656D-4DE9-AE69-BEDE8C0F4E9C
P2860
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@ast
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@en
type
label
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@ast
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@en
prefLabel
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@ast
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@en
P2093
P50
P356
P1476
Bortezomib-melphalan-prednison ...... llow-up and improved survival.
@en
P2093
Antonietta Pia Falcone
Chiara Nozzoli
Daniela Gottardi
Davide Rossi
Fortunato Morabito
Francesca Patriarca
Giulia Benevolo
Iolanda Donatella Vincelli
Luca Franceschini
P304
P356
10.1200/JCO.2013.52.0023
P407
P50
P577
2014-01-21T00:00:00Z